{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:17:21Z","timestamp":1790626641895,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neuroendocrine tumors have increased in prevalence and diversity in recent years and are often diagnosed at metastatic stages. Compared with nonradioactive systemic treatment with somatostatin analogs, peptide receptor radionuclide therapy (PRRT) has shown superior overall survival benefits for well-differentiated neuroendocrine tumor patients. This study aimed to identify biomarkers from <jats:sup>68<\/jats:sup>Ga\u2012DOTATOC PET\/CT scans to predict survival in patients treated with PRRT in the clinic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>This retrospective study analyzed <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT data from 67 NET patients undergoing PRRT. Tumor volumes and SUV metrics were segmented using standardized protocols. Radiomics features from liver metastases were extracted and preprocessed for analysis. Data were analysed via Kaplan-Meier, Cox regression, and PCA to evaluate the prognostic value of volumetric-, radiomics-, and clinicopathological parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included scans from 67 patients with an average age of 67 years. The mean survival time was 46.5 months, with 43% of patients alive or lost to follow-up at the conclusion of data collection. Despite comprehensive analyses, neither volumetric parameters, including total tumor volume and organ-specific tumor volume, nor SUV values (SUVmax and SUVmean) were robust predictors of overall survival. K\u2012M and Cox regression analyses revealed no significant differences in survival between the high- and low-risk groups for these parameters. Furthermore, radiomics features extracted from liver metastases did not demonstrate significant prognostic value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Quantification of <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT-derived parameters offers limited prognostic value for OS in NET patients who are receiving PRRT in clinical practice. These findings might emphasize the current robust integration of imaging in clinical decision-making for NET management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00899-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:46:40Z","timestamp":1751359600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Imaging-derived biomarkers from 68Ga-DOTATOC PET\/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with 177Lu-DOTATATE"],"prefix":"10.1186","volume":"25","author":[{"given":"Stephan","family":"Raad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Fatlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Louise","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fottner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Schadmand-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Musholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"899_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.114.148247","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, et al. Impact of 68 Ga-DOTATATE PET\/CT on the management of neuroendocrine tumors: the referring physician\u2019s perspective. J Nucl Med. 2015;56(1):70\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"899_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12885-020-06836-y","volume":"20","author":"M Weber","year":"2020","unstructured":"Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET\/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer. 2020;20(1):326.","journal-title":"BMC Cancer"},{"issue":"6","key":"899_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","volume":"10","author":"MH Kulke","year":"2012","unstructured":"Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, et al. Neuroendocrine Tumors J Natl Compr Canc Netw. 2012;10(6):724\u201364.","journal-title":"Neuroendocrine Tumors J Natl Compr Canc Netw"},{"issue":"3","key":"899_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313\u20138.","journal-title":"Mol Imaging Biol"},{"key":"899_CR5","first-page":"41","volume":"58","author":"D H\u00f6rsch","year":"2016","unstructured":"H\u00f6rsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer Oxf Engl 1990. 2016;58:41\u201351.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"5","key":"899_CR6","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","volume":"44","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44(5):e329\u201335.","journal-title":"Clin Nucl Med"},{"key":"899_CR7","doi-asserted-by":"publisher","first-page":"1169970","DOI":"10.3389\/fmed.2023.1169970","volume":"10","author":"NF Trautwein","year":"2023","unstructured":"Trautwein NF, Schwenck J, Jacoby J, Reischl G, Fiz F, Zender L, et al. Long-term prognostic factors for PRRT in neuroendocrine tumors. Front Med. 2023;10:1169970.","journal-title":"Front Med"},{"issue":"7","key":"899_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.119.236935","volume":"61","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Van Binnebeek S, Vandecaveye V, Baete K, Vanbilloen H, Koole M, et al. Inflammation-Based index and 68 Ga-DOTATOC PET\u2013Derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90 Y-DOTATOC. J Nucl Med. 2020;61(7):1014\u201320.","journal-title":"J Nucl Med"},{"issue":"10","key":"899_CR9","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"on behalf of the NETTER-1 study group, Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"899_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of 68 Ga-OPS202 and 68 Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: A prospective phase II imaging study. J Nucl Med. 2018;59(6):915\u201321.","journal-title":"J Nucl Med"},{"issue":"4","key":"899_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13139-015-0356-y","volume":"49","author":"I Lee","year":"2015","unstructured":"Lee I, Paeng JC, Lee SJ, Shin CS, Jang JY, Cheon GJ, et al. Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET\/CT and 111In-Pentetreotide SPECT\/CT in neuroendocrine tumors: a preliminary report. Nucl Med Mol Imaging. 2015;49(4):284\u201390.","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"899_CR12","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.18632\/oncotarget.12402","volume":"8","author":"RA Werner","year":"2017","unstructured":"Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2017;8(4):7039\u201349.","journal-title":"Oncotarget"},{"issue":"3","key":"899_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, Ilhan H, Lehner S, Papp L, Zs\u00f3t\u00e9r N, Schatka I, et al. Pre-therapy somatostatin receptor-Based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21(3):582\u201390.","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"899_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2967\/jnumed.121.262782","volume":"63","author":"RP Reddy","year":"2022","unstructured":"Reddy RP, Ross Schmidtlein C, Giancipoli RG, Mauguen A, LaFontaine D, Schoder H, et al. The quest for an accurate functional tumor volume with68 Ga-DOTATATE PET\/CT. J Nucl Med. 2022;63(7):1027\u201332.","journal-title":"J Nucl Med"},{"issue":"10","key":"899_CR15","doi-asserted-by":"publisher","first-page":"e19304","DOI":"10.1097\/MD.0000000000019304","volume":"99","author":"Lfan Wang","year":"2020","unstructured":"Wang Lfan, Lin L, Wang Mjiao, Li Y. The therapeutic efficacy of 177Lu-DOTATATE\/DOTATOC in advanced neuroendocrine tumors: A meta-analysis. Med (Baltim). 2020;99(10):e19304.","journal-title":"Med (Baltim)"},{"issue":"5","key":"899_CR16","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"899_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4149\/neo_2018_180328N209","volume":"66","author":"J Ohnona","year":"2019","unstructured":"Ohnona J, Nataf V, Gauthe M, Balogova S, Belissant Benesty O, Zhang-Yin J, et al. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET\/CT in patients with pancreatic neuro-endocrine tumors. Neoplasma. 2019;66(1):140\u20138.","journal-title":"Neoplasma"},{"issue":"4","key":"899_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/diagnostics13040606","volume":"13","author":"L Urso","year":"2023","unstructured":"Urso L, Castello A, Treglia G, Panareo S, Nieri A, Rambaldi I, et al. Relevance of volumetric parameters applied to [68Ga]Ga-DOTATOC PET\/CT in NET patients treated with PRRT. Diagnostics. 2023;13(4):606.","journal-title":"Diagnostics"},{"issue":"1","key":"899_CR19","doi-asserted-by":"publisher","first-page":"9758","DOI":"10.1038\/s41598-021-89114-6","volume":"11","author":"E Chang","year":"2021","unstructured":"Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, et al. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Sci Rep. 2021;11(1):9758.","journal-title":"Sci Rep"},{"issue":"8","key":"899_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"899_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/fdg PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149\u201358.","journal-title":"Theranostics"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00899-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:46:41Z","timestamp":1751359601000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00899-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00899-5","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective analysis was performed in accordance with the requirements of the competent ethics committee (Landes\u00e4rztekammer Rheinland-Pfalz). Informed consent to obtain and analyze patient data was given within a German registry study approved by the local ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}